Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

ADDvise Group, Audiocast with teleconference, Q2'24

By Inderes7/18/2024, 12:00 PM
ADDvise Group

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Rikard Akhtarzand
00:01 - 16:10

Thank you. And once again, welcome to ADDvise Group 2024 Second Quarter Earnings Call. The second quarter this year showed mixed financial performance. Our net sales came in at 412 million SEK. Which reflects a year-on-year growth of 20%. However, we faced challenging pharma and clinical trial comparables following last year's exceptional performance in two of our businesses. This resulted in a negative organic growth isolated to the quarter of -21%. Just to provide some context on the underlying businesses, Normally, I don't adjust for items, but just to signify the impact of these two businesses and how the rest of the 19 businesses performed. After excluding the two exceptional businesses, Forma Pharma and European clinical trials. Without these two, our isolated organic growth for the quarter would have been 13%. Of course, the reported number is what it is, but this provides more clarity on the negative organic growth. It's worth mentioning that the two businesses that outperformed last year are still aligning with or exceeding the performance they had when we acquired them, even though they are not at last year's levels during 2024. EBITDA came in at 102 million, resulting in an unadjusted EBITDA margin of 25%. We had our best quarter ever in terms of order intake. Overall, the order intake came in at 67% and 13% respectively; This was measured by organic levels. Specifically, within our laboratory segment, you can find the drivers behind these large numbers. As you recall from last year, we did not achieve the desired cash conversion from operating earnings down to net profit. A few reasons were the tax inefficiencies in our ADDvise group last CY. Also, significant depreciation due to a large volume of clinical trial rental revenues affected our calculations. So, we have put a lot of effort into minimizing the disparity between operating profit and the final net profit, which we have succeeded in doing. Looking at the net profitability for the quarter, we are sitting at around 30 million SEK compared to 3 million last year. Earnings per share were 0.15 SEK. This is an improvement compared to last year. Assessing the cash flow for the quarter leaves me unsatisfied, due to some net working capital buildup influenced by the product mix, something that I will address later in the presentation. Our liquidity is strong, with over 400 million in cash and cash equivalents and an undrawn credit facility on top of that. In our Nordic businesses, we witnessed strong momentum this quarter. As mentioned earlier, the demand for climate and clean room solutions outperformed this quarter. This demand, geographically driven by our Middle Eastern customers, is motivated by their desire to reduce oil dependency and invest in more sustainable businesses in that region. This sustainability focus bolsters research and pharma development, which in turn drives demand in our businesses operating in climate and clean room solutions. In May, we also secured our largest single order to date, $11.3 million to an Omani customer building a research facility in Oman. South America is also a strong market for us currently. We see high growth rates in that region and our businesses operating in Brazil. I have very good momentum. Unfortunately, that business is not part of the organic growth calculation yet, because we haven't owned that business for 12 months. So that will come into the numbers. It will be included as of the fourth quarter this year. As mentioned before, the clinical trials saw some challenging comparables after the exceptional year in 2023. But that is only in the European part of the clinical trials business. Our recently acquired North American business within clinical trials is performing according to or slightly above the levels we were promised before the acquisition. The same thing applies here; they're not part of the organic growth calculation. It will come into the numbers later this year. The demand for capital goods in the US remains a bit soft in the quarter. We saw some improvement late in the second quarter. The signals we get from our customers suggest that interest rates still hurt investment in capital equipment. When the Fed starts to cut interest rates, we believe the demand in that market will bounce back. In terms of geography, 44% of our sales in the quarter came from North America. Our main US market, the second largest for us, is Europe, excluding Sweden. And the third one is South America. So we have a well-diversified geographical exposure in the ADDvise group. As we stand today, looking at the four or five product categories that we measure, the largest one year-to-date in the second quarter is laboratory equipment, followed by medical consumables and medical equipment. As you can see on this pie chart, pharma is now down at 7% of ADDvise group's sales. Year to date in the second quarter. If you compare that to last year, we were around 20-25% of ADDvise group sales, and as I've said several times before, the pharma revenues that we have come with much higher margins. But at the same time, the flip side of that is that the revenues are more volatile than the rest of our ADDvise group. But when we are down at 7 or 8% where we are right now, I see the volatility on the upside rather than the downside. So for us, the 7% that we see today are very robust compared to where we were last year. On this slide, you see the growth trajectory over the last four years. As you can see, we have, for the first time, surpassed 1.5 billion SEK in sales. And if you look at the quarter isolated, we came in at 412 million SEK. Organic growth dropped 21% due to the reasons I just mentioned. At the ADDvise group level, we split our revenues between our own proprietary products, which we develop and manufacture, and products that we distribute, which we do not own; and in the second quarter, year-to-date, our own products accounted for close to 60% of our sales. And that is typically the balance that we would like to have going forward. Around 60% owned products and 30%-35% distribution and the rest as service revenues. Order intake was the strongest quarter ever at 134 million. 67% total growth in order intake. Organically, 13% up. The main driver, as mentioned, several companies contributed to the growth. But the main driver that stands out was the laboratory, clean room, and climate room solutions that boosted the order intake in the quarter. So going into the second half of this year, we have a solid order backlog to convert into sales in the upcoming quarters, dividing our advice group into healthcare and lab segments, focusing on healthcare. Our sales came in at 256 million in the quarter. Organic growth dropped 12%. If you exclude the pharma revenues from this segment, the organic growth would have been 9% in the quarter. This discrepancy essentially skews the numbers between the two businesses. One is in the healthcare segment and the other in the laboratory segment. Total sales grew by 28% in the quarter. We closed the quarter with a 19% EBIT Wild margin. Looking at the laboratory segment, slightly smaller as part of the advice group, with sales of 157 million. Organic growth was at -33%. Following the same calculation here, stripping out European clinical trial business, the organic growth would have been 24% in the quarter, isolated margin-wise with an operating margin of 25% in the quarter. In isolated geography, you can see on the pie charts that we have slightly different geographical exposures in the two segments. North America is the key market for the healthcare segment and will continue to be that for a long time. However, South America is a very fast-growing market compared to the other markets, which are slightly more mature. South America is a very fast-growing market. In the laboratory segment, the rest of the world is now the largest market for us. This is driven by, as I mentioned in the presentation earlier, Middle Eastern customers investing heavily in sustainable businesses, most of all in research and pharma businesses. We supply them with clean room facilities, climate rooms, and equipment used in these facilities. Europe, excluding Sweden, is the second-largest market, and 25%, or a quarter of the sales, comes from Sweden. And that is, of course, where it all started for the ADDvise group, many years ago in Sweden. Financial performance. We are now on a rolling 12-month basis at around 420 million in EBITDA. On a margin level, we achieved a rolling 12-month margin of 27% and isolated in the quarter at 25%. The drop in margin is mainly affected by the product mix. As mentioned before, Pharma, which is a much smaller portion of our ADDvise group today compared to last year, comes with a much higher margin compared to the project business for clean rooms and climate rooms, which carries a lower margin. And that, of course, affects the group margin. Margin. Weaker operating earnings but improved net profitability. Our EBITDA came down from 122 million to 102 million in the quarter. And if you look at earnings before interest and tax, you saw a drop of 8% from 87 to 80. On the other hand, net profitability increased significantly from 3 million to 30 million. Um, and the drivers for the increased net profitability are several. It's a more tax-efficient structure, improving the, uh, or lowering the tax rate. A lower amount of depreciation in the quarter was based on a reduced volume of clinical trial rental business.

Unknown 1
16:11 - 16:11

Um.

Rikard Akhtarzand
16:12 - 23:31

In the second quarter last year, we also had the cost for refinancing our SEK-denominated bond. Additionally, we experienced positive effects in the second quarter of this year from the net effect of write-ups and write-downs of our notes during the quarter. I'm not happy with the cash flow in the quarter. We had a significant working capital buildup in the quarter, which is something that we are taking seriously, and we are working hard now to improve that in the upcoming quarters, to conclude the year in strong fashion on cash conversion and cash flow. That also means that the return on capital employed was lower, isolated in the second quarter. Compared to the first quarter, and hopefully by late this year, we will be back on track with return on capital employed. Our financial position remains solid. We are below our long-term leverage target. We are now at 2.9 times in net leverage. We have a strong financial position with 130 million SEK in liquidity. That is cash in the bank and cash equivalents. And we also have an undrawn credit facility. Net leverage is 2.9 pro forma. Leverage is, of course, a big focus area for us. Uh, and that goes into our M&A strategy. We are cautiously evaluating potential M&A deals, keeping our net leverage in mind. And, of course, we prioritize deals where we can see immediate or fast deleveraging. On the deals, we can finalize and we have a few of them in the pipeline that we are evaluating right now, and hopefully we can finalize one or two before the end of the year, but no promises on that yet. And our first major debt maturity is not until May 2026. This is my final and 55th interim report as CEO for ADDvise. I would like to provide you with a few key takeaways from the second quarter, along with a brief recap and historical overview. Before I open up the floor for questions and in a few weeks hand over the CEO chair to my successor, I'd like to thank the staff and host. Key takeaways from the quarter. Sales growth totaled 20%. Uh, very strong order intake growth. 67% and double-digit organic profitability product mix resulted in weaker but still robust profitability. We have made improvements in converting operating profitability into net profitability. Especially on the tax efficiency in the group and also when it comes to depreciation, cash flow. Not in line with my expectations. Working capital build-up. We are on that, and I believe that during the second half of this year, we will see improvements. Ample liquidity. On the M&A side, we cautiously monitor net leverage and keep that in mind for every deal that we evaluate. Hopefully, we will finalize something before the end of this year. As I said, this is my 55th and final report. Interim report for ADDvise Group. And, I just want to give you a small historical exposé on the columns that you see in the chart on the right-hand side. The first quarter I reported in 2010, ADDvise Group had 11 million SEK in sales. It was a very small local laboratory equipment supplier, focusing primarily on the Swedish market, but more specifically on the Stockholm region. In the second quarter this year, more than 14 years later, we came in at 412 million in sales. In the first quarter, we didn’t make any profit. It was zero, basically. This year, in the second quarter, we came in above 100 million in operating profit or EBITDA profitability. So it has been quite a journey. I would like to take the opportunity to thank all the team members of the ADDvise group who have stood by my side for these 14, or more than 14 years. I would like to take the opportunity to thank the board members, the investors, and all the stakeholders who have been part of this journey and believed in it, because it has been a fantastic journey for me and for many people in the organization and the businesses. And, last but not least, for our customers, with the products and services that we put on the market. So with that said. I'm handing over the CEO chair to my successor, Mr. Stofan, and so on. I am 100% sure that he will take our advice group to new heights. So with that, I open up the floor for questions.

Operator
23:34 - 24:02

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Philip Eichengreen from ABG Sundal Collier. Please go ahead.

Unknown 2
24:03 - 24:30

Thank you, Operator. And good afternoon. To start, I would just like to get some more color on the healthcare segment. So you noted it declined organically, mainly due to the generic pharma business, but are there any other businesses within this segment that are also progressing negatively in the quarter? And also, regarding pharma. What type of visibility do you have for the rest of the year?

Rikard Akhtarzand
24:33 - 26:03

As you know, we do not report on the unit level. We report on the segment level. But I mean, we have a number of businesses. The majority of the businesses are performing in line or above our expectations if you exclude the generic drug business. So, I'm very confident that once the skewed numbers roll out, which they do kind of in the back end of the fourth quarter this year, and with the four new businesses coming into our organic growth calculation, we will be back on organic growth mid to late fourth quarter this year. And we have a pipeline of products that we are bringing to the market in the revenue stream of pharma businesses. So I would say, and I think I mentioned during the presentation that the volatility is still in the pharma segment, but right now we are at very low levels in terms of sales in the pharma segment in the second quarter. So the volatility is on the upside in the pharma business. So, that is kind of a summary of the healthcare segment.

Unknown 2
26:05 - 26:18

Okay. And if we move on to the lab segment, then there was substantial growth in orders, as I talked about. Now, when can we expect these to start to materialize? When can we see it on sales?

Rikard Akhtarzand
26:18 - 27:16

And you will see that gradually. <grid /> And of course, some of it came in already in the second quarter. But as you know, with large projects, some of these projects run from 12 to 24 months. So we have typically the same kind of revenue recognition as you would find in a construction company. You recognize revenues in line with the amount of effort or work you put in. But that is not always aligned with cash flow, and that is the reason why you see the working capital build up in the quarter. So we have a very solid order backlog now in our ADDvise group, giving us good visibility on the upcoming quarters. So some of it, a small portion of the large order intake you already saw in the second quarter. But most of these orders run for 12 to 24 months, the big ones.

Unknown 2
27:18 - 27:45

Perfect, thank you. In Q3 last year, we experienced some negative organic growth, yet in Q4, it was quite positive. What can we expect for the remainder of this year? Will Q3 continue to be soft, or will growth pick up in Q4? How should we think about that balance, considering the comps you face?

Rikard Akhtarzand
27:45 - 28:33

As I mentioned, we have one business in the lab segment and another in the healthcare segment, which skews the numbers. So it will be difficult to achieve organic growth, at least on a group level, until the middle of the fourth quarter this year. If you look at the first quarter this year, we didn't have any skewed numbers in the laboratory segment. We only had skewed numbers in the healthcare segment. It's extremely hard for me to say exactly when you will see organic growth on a segment level. In my view, by the middle of the fourth quarter this year, we will be back to experiencing organic growth at the group level.

Unknown 2
28:36 - 28:53

Okay. But just to get the full picture correct here. So, should we assume that both segments will achieve organic growth in Q4, or will one segment drag the other down? I know this is a hard question, of course, but.

Rikard Akhtarzand
28:54 - 29:55

In the third quarter, obviously, as soon as I say that, the group will be back by mid to late fourth quarter. My view on the third quarter is that we will not have organic growth at the group level. And I would like to, uh, um. I don't want to delve into the segments and provide numbers at the segment level regarding my expectations for organic growth. I just want to keep that at the group level because I don't have 100% visibility on that. It's much harder to see that on a segment level. But what I can say is that when we enter the fourth quarter this year, the skewed numbers or the exceptional levels that we saw last year will roll out from the numbers, starting maybe. If I remember correctly, mid-November-ish.

Unknown 1
29:55 - 29:56

Huh?

Unknown 2
29:58 - 30:13

Thank you. And if we move on to gross margins, they were down across the board this quarter. Of course, the top line was down, but what can we expect for H2? Do you have any visibility on that?

Rikard Akhtarzand
30:14 - 30:37

I think that if you look at the third quarter, I believe that we will be pretty much in line with where we are now or slightly better. And then, of course, working on pricing and the initiatives that we always work with, aiming for gradual improvement.

Unknown 2
30:40 - 30:43

Perfect, thank you. Lastly, from me, is there?

Unknown 3
30:43 - 30:44

Sorry, but it seems there might have been a misunderstanding.

Rikard Akhtarzand
30:44 - 31:15

One more comment on that. And just to clarify, I mean, we finalized four large acquisitions by the end of last year. And we obviously have a playbook to improve businesses and work together with local management to improve pricing, gross margin, etc. But we can't do that on day one. It's a gradual improvement before we start seeing the effects of the initiatives that we take.

Unknown 2
31:18 - 31:27

Perfect. That sounds reasonable. And lastly, is there anything else we should be mindful about for the rest of the year? Anything we missed? Anything not covered here?

Rikard Akhtarzand
31:28 - 32:33

No. I think the most important thing is clarification, and as I said, I hate stripping things out just to show you good numbers, but that's not my intention. But in order to give you context, since we had such incredible performance in two businesses last year, I am just lifting the bonnet and showing you how it would have looked if we stripped these out. That is the key takeaway here. We will be back with solid organic growth, but it will not happen in the third quarter. But it will happen later this year. And then we are back to normalized levels. That is the key takeaway here. We have solid businesses that perform organic growth. Not 100% of the businesses do that every year, but the large majority of the businesses perform in line with our expectations or above our expectations, though they are skewed now because of the exceptional performance in two businesses last year.

Unknown 2
32:36 - 32:38

Perfect. Thank you. I'll get back into the queue.

Operator
32:43 - 32:48

The next question comes from Kristian Binder from Redeye. Please go ahead.

Unknown 4
32:53 - 33:18

And thanks so much for taking my question. Most of them have already been answered. But one additional question around M&A. You said that you hope to maybe finalize something this year, but given the slightly elevated net leverage towards the upper end of your target and the leadership transition, should we still expect it to be more likely for M&A to resume next year?

Rikard Akhtarzand
33:20 - 34:29

I mean, if one of the criteria in the M&A strategy is to deliver, then of course you narrow down the pipeline and you don't get as many prospects as you had when you were able to pay more in line with historical multiples. So, of course it takes a little bit more time, but we have a few businesses where we see that we can deliver immediately or very close to the acquisition date. And that is something that we would like to do because for us to have 430 million sitting in the bank, that is a huge cost for us and the shareholders. At the times we are extremely cautious about that leverage. So that's kind of the balancing act for us. It takes a little more time to find the exactly right acquisition when you have deleveraging as one of the search criteria.

Unknown 4
34:32 - 34:40

Okay. Got it then. Just to clarify, you don't think the leadership transition will slow down the pace of M&A in any way?

Rikard Akhtarzand
34:41 - 36:08

No, I mean, for the last or the first ten years, I was actually heading M&A at ADDvise Group. But for the last four years, we have had a solid team working on M&A independently of me. Of course, I've been part of the team that approves or disapproves potential M&A deals. But the M&A team is still active. We have the same people, and it's not part of the leadership. And even more so when bringing staff on board. He has 20 years of experience in capital markets, of which 15 to 17 years are within M&A and corporate finance. So I think that bringing staff on board improves the M&A process even more. But still, the M&A team is run by our head of legal and M&A, Hannah, with her team members. So that is my answer to that. I think we will be at the same level in M&A capacity or even better with staff on board.

Unknown 4
36:10 - 36:12

Perfect. Got it. Also from my side. Thank you so much.

Unknown 1
36:13 - 36:13

Thanks.

Operator
36:18 - 36:25

As a reminder, if you wish to ask a question, please dial pound key five on your telephone keypad.

Unknown 5
36:34 - 36:39

There seems to be no more questions for today, so thank you everyone for listening and have a nice day.

Unknown 1
36:41 - 36:41

Thank king you.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…